Skip to main content

Table 2 Interacting kinetics of bevacizumab and FD006 binding to VEGF

From: Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization

  KD (M) Kon (1/Ms) Kdis (1/s) Full R2
bevacizumab 6.50E-10 1.75E + 05 1.02E-04 0.992536
FD006 3.11E-10 1.48E + 05 4.59E-05 0.992964